Pharmaceutical manufacturer Adcock Ingram has warned investors that profit margins on its portfolio of medicines that are subject to government price controls will remain under pressure, despite the “top up” increase announced in July. 

Health minister Joe Phaahla agreed to a rare mid-year price increase for private-sector medicine sales in July, allowing companies to raise the single exit price (SEP) of eligible products by up to 1.73%, on top of the 3.28% increase announced last December. The “top up” increase, which would take effect in September, was a welcome development but was still not enough to completely offset inflation, said Adcock Ingram CEO Andy Hall...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.